Curanex Pharmaceuticals Inc
CURX
$0.32
-$0.01-3.73%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 2.31M | 677.50K | -- | -- | -- |
| Gross Profit | -2.31M | -677.50K | -- | -- | -- |
| SG&A Expenses | 786.30K | 273.90K | 57.70K | 137.50K | 72.70K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.09M | 951.30K | 57.70K | 137.50K | 72.70K |
| Operating Income | -3.09M | -951.30K | -57.70K | -137.50K | -72.70K |
| Income Before Tax | -3.07M | -954.10K | -60.30K | -137.60K | -145.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.07M | -954.10K | -60.30K | -137.60K | -145.90K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.07M | -954.10K | -60.30K | -137.60K | -145.90K |
| EBIT | -3.09M | -951.30K | -57.70K | -137.50K | -72.70K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.11 | -0.04 | 0.00 | -0.01 | 0.00 |
| Normalized Basic EPS | -0.07 | -0.02 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.11 | -0.04 | 0.00 | -0.01 | 0.00 |
| Normalized Diluted EPS | -0.07 | -0.02 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 28.37M | 25.60M | 24.00M | 24.00M | 40.44M |
| Average Diluted Shares Outstanding | 28.37M | 25.60M | 24.00M | 24.00M | 40.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |